Article info
PDFEconomic analysis
Screening for postmenopausal osteoporosis with any modality is cost-effective including screening initiation at 55 years of age
- Correspondence to: Gavin Peter Ross Clunie
Department of Rheumatology, The Ipswich Hospital, Heath Rd, Ipswich, Suffolk IP4 5PD, UK; gavin.clunie{at}doctors.org.uk
Citation
Screening for postmenopausal osteoporosis with any modality is cost-effective including screening initiation at 55 years of age
Publication history
- First published July 10, 2012.
Online issue publication
October 25, 2017
Article Versions
- Previous version (25 October 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions